Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keigo Komine

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 15, 2023
[Current Status and Challenges in Tumor Agnostic Treatment]Keigo Komine
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 24, 2020
[The Role of Core Hospital of Cancer Genomic Medicine and Regional Cooperation]Hidekazu Shirota, Keigo Komine
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 6, 2019
[Interinstitutional Collaboration for Molecular Tumor Boards]Keigo Komine, Hidekazu Shirota
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 22, 2009
[Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment]Hideki Shimodaira, Hiroshi Soeda, Keigo Komine, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 25, 2010
[Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody]Hideki Shimodaira, Keigo Komine, Hiroshi Soeda, et al.
BMC Palliative Care|October 30, 2013
Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancerHiroo Imai, Hiroshi Soeda, Keigo Komine, et al.
Cancer Science|July 21, 2021
Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancerSakura Hiraide, Masanobu Takahashi, Yuya Yoshida, et al.
Anticancer Research|February 9, 2013
Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancerKazunori Otsuka, Hiroo Imai, Hiroshi Soeda, et al.
Cancer Science|August 23, 2024
Tretinoin synergistically enhances the antitumor effect of combined BRAF, MEK, and EGFR inhibition in BRAF<sup>V600E</sup> colorectal cancerYuya Yoshida, Masanobu Takahashi, Sakura Taniguchi, et al.
Anticancer Research|June 13, 2014
Utility of measuring circulating tumor cell counts to assess the efficacy of treatment for carcinomas of unknown primary originKeigo Komine, Masahiro Inoue, Kazunori Otsuka, et al.
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 15, 2023
[Current Status and Challenges in Tumor Agnostic Treatment]Keigo Komine
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 24, 2020
[The Role of Core Hospital of Cancer Genomic Medicine and Regional Cooperation]Hidekazu Shirota, Keigo Komine
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 6, 2019
[Interinstitutional Collaboration for Molecular Tumor Boards]Keigo Komine, Hidekazu Shirota
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 22, 2009
[Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment]Hideki Shimodaira, Hiroshi Soeda, Keigo Komine, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 25, 2010
[Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody]Hideki Shimodaira, Keigo Komine, Hiroshi Soeda, et al.
BMC Palliative Care|October 30, 2013
Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancerHiroo Imai, Hiroshi Soeda, Keigo Komine, et al.
Cancer Science|July 21, 2021
Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancerSakura Hiraide, Masanobu Takahashi, Yuya Yoshida, et al.
Anticancer Research|February 9, 2013
Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancerKazunori Otsuka, Hiroo Imai, Hiroshi Soeda, et al.
Cancer Science|August 23, 2024
Tretinoin synergistically enhances the antitumor effect of combined BRAF, MEK, and EGFR inhibition in BRAF<sup>V600E</sup> colorectal cancerYuya Yoshida, Masanobu Takahashi, Sakura Taniguchi, et al.
Anticancer Research|June 13, 2014
Utility of measuring circulating tumor cell counts to assess the efficacy of treatment for carcinomas of unknown primary originKeigo Komine, Masahiro Inoue, Kazunori Otsuka, et al.
Pageof 8